Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philippa Easterbrook

Showing results (111-120 of 143) with videos related to

Pageof 15
Sort By:
Plos One|August 11, 2016
Facility-Level Factors Influencing Retention of Patients in HIV Care in East AfricaBeth Rachlis, Giorgos Bakoyannis, Philippa Easterbrook, et al.
AIDS (London, England)|June 26, 2007
Increased duration of viral suppression is associated with lower viral rebound rates in patients with previous treatment failuresAndrew A Benzie, Loveleen K Bansi, Caroline A Sabin, et al.
The Journal of Antimicrobial Chemotherapy|November 10, 2009
Factors influencing lopinavir and atazanavir plasma concentrationWolfgang Stöhr, David Back, David Dunn, et al.
BMC Infectious Diseases|November 17, 2017
Trends in hepatitis B virus testing practices and management in HIV clinics across sub-Saharan AfricaPatrick A Coffie, Matthias Egger, Michael J Vinikoor, et al.
The Lancet. Infectious Diseases|November 8, 2017
Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trialJames G Hakim, Jennifer Thompson, Cissy Kityo, et al.
Blood|April 6, 2013
Correlates of T-cell-mediated viral control and phenotype of CD8(+) T cells in HIV-2, a naturally contained human retroviral infectionThushan I de Silva, Yanchun Peng, Aleksandra Leligdowicz, et al.
AIDS (London, England)|September 12, 2008
Treatment switches after viral rebound in HIV-infected adults starting antiretroviral therapy: multicentre cohort study, Katherine J Lee, David Dunn, et al.
AIDS (London, England)|August 11, 2007
Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell countAndrew N Phillips, Brian Gazzard, Richard Gilson, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 21, 2021
Outcomes of the CT2 study: A 'one-stop-shop' for community-based hepatitis C testing and treatment in Yangon, MyanmarBridget Louise Draper, Hla Htay, Alisa Pedrana, et al.
The Lancet. Child & Adolescent Health|March 20, 2025
Simplifying medicine dosing for children by harmonising weight bands across therapeutic areasHylke Waalewijn, Mounier Almett, Roeland E Wasmann, et al.
Pageof 15

Showing results (111-120 of 143) with videos related to

Sort By:
Pageof 15
Plos One|August 11, 2016
Facility-Level Factors Influencing Retention of Patients in HIV Care in East AfricaBeth Rachlis, Giorgos Bakoyannis, Philippa Easterbrook, et al.
AIDS (London, England)|June 26, 2007
Increased duration of viral suppression is associated with lower viral rebound rates in patients with previous treatment failuresAndrew A Benzie, Loveleen K Bansi, Caroline A Sabin, et al.
The Journal of Antimicrobial Chemotherapy|November 10, 2009
Factors influencing lopinavir and atazanavir plasma concentrationWolfgang Stöhr, David Back, David Dunn, et al.
BMC Infectious Diseases|November 17, 2017
Trends in hepatitis B virus testing practices and management in HIV clinics across sub-Saharan AfricaPatrick A Coffie, Matthias Egger, Michael J Vinikoor, et al.
The Lancet. Infectious Diseases|November 8, 2017
Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trialJames G Hakim, Jennifer Thompson, Cissy Kityo, et al.
Blood|April 6, 2013
Correlates of T-cell-mediated viral control and phenotype of CD8(+) T cells in HIV-2, a naturally contained human retroviral infectionThushan I de Silva, Yanchun Peng, Aleksandra Leligdowicz, et al.
AIDS (London, England)|September 12, 2008
Treatment switches after viral rebound in HIV-infected adults starting antiretroviral therapy: multicentre cohort study, Katherine J Lee, David Dunn, et al.
AIDS (London, England)|August 11, 2007
Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell countAndrew N Phillips, Brian Gazzard, Richard Gilson, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 21, 2021
Outcomes of the CT2 study: A 'one-stop-shop' for community-based hepatitis C testing and treatment in Yangon, MyanmarBridget Louise Draper, Hla Htay, Alisa Pedrana, et al.
The Lancet. Child & Adolescent Health|March 20, 2025
Simplifying medicine dosing for children by harmonising weight bands across therapeutic areasHylke Waalewijn, Mounier Almett, Roeland E Wasmann, et al.
Pageof 15